ALLMedicine™ Allergic Contact Dermatitis Center

Aug 12th, 2022 - The study will investigate if Anakinra can ameliorate allergic contact dermatitis in participants with known nickel allergy

Aug 10th, 2022 - Procedures Patch testing (see the image below) is useful to distinguish irritant reactions from allergic reactions. [54, 55, 56, 57] Patch testing before placement of a prosthesis is not indicated. Reading at 10 days is recommended because reactio...

Aug 9th, 2022 - Dermatitis localized to hands (HD), feet (FD), or both hands and feet (HFD) has multiple etiologies including atopic dermatitis (AD), irritant contact dermatitis (ICD), and allergic contact dermatitis (ACD). Little is known about clinical differen...

Jul 31st, 2022 - Gel nail polish (GNP) has recently gained worldwide popularity. We have conducted a comprehensive summary of the complications of GNP through a literature search using PubMed, Scopus, and Google Scholar databases to identify eligible papers. Compl...

Jul 27th, 2022 - Practice Essentials Atopic dermatitis (AD) is a chronically relapsing skin disorder with an immunologic basis. [1] The clinical presentation varies from mild to severe. In the worst cases, atopic dermatitis may interfere with normal growth and dev...

Nov 12th, 2021 - Standard patch test screening, which tests for up to 70 allergens for patients with allergic contact dermatitis, is limited and may miss many allergens, a study published in JAMA Dermatology has found. Dr Erin M. Warshaw The cross-sectiona...

Aug 20th, 2015 - Allergic contact dermatitis (ACD) in children appears to be on the increase, and contact sensitization may already begin in infancy. The diagnosis of contact dermatitis requires a careful evaluation of a patient's clinical history, physical examin...

Aug 12th, 2022 - The study will investigate if Anakinra can ameliorate allergic contact dermatitis in participants with known nickel allergy

Apr 21st, 2022 - Study participation involves three visits to the study site on Days 1, 3, and 5, and completion of a demographics and allergy history questionnaire. Researchers will review medical history and current medications. On Day 1 a patch will be applied ...

Apr 1st, 2022 - The purpose of this study is to evaluate the safety and efficacy of EB01 Cream (0.2%, 1.0%, 2.0%) applied twice per day (BID) for the treatment of moderate to severe chronic allergic contact dermatitis (ACD). The purpose of the open label extensio...

Jan 28th, 2022 - The treatment of allergic contact dermatitis (ACD) can be unsatisfactory, and that other skin diseases such as atopic dermatitis have an increased likelihood of ACD, improved systemic treatments are needed. This research study explores the effecti...

Dec 17th, 2021 - This study will involve 2 regimens which will run in parallel. Each participant's upper back will be divided into 2 equal spaces for Regimen 1 and 2. Each of the 4 treatment sites in each space will be independently randomized to placebo or rHuPH2...

Aug 8th, 2022 - Isocyanate adhesives found in polyurethane (PU)–based diabetes devices and wound dressings may cause allergic contact dermatitis (ACD), results of a small case series suggest. "Isocyanates, widely used in the production of paints, coatings, glues,...

Jul 8th, 2022 - An ancient tree of the Ginkgoaceae family, Ginkgo biloba is known as a living fossil because its genome has been identified in fossils older than 200 million years. 1 An individual tree can live longer than 1000 years.

Jul 8th, 2022 - No time of the year is more exciting than the unveiling of the American Contact Dermatitis Society Allergen of the Year. Sometimes the selected allergen represents a completely novel cause of allergic contact dermatitis (ACD) with an unpronounceab.

Jul 7th, 2022 - Various ingredients in topical eye medications may be causing allergic contact dermatitis at higher rates than assumed, a small retrospective cohort study suggests. "Allergic contact dermatitis caused by topical ophthalmic medications (OftACD) is ...

May 17th, 2022 - Dupilumab is a humanized monoclonal antibody approved by the US Food and Drug Administration (FDA) for the treatment of moderate to severe atopic dermatitis. Through inhibition of the IL-4R α subunit, it prevents activation of the IL-4/IL-13 signa.